Gimme Care Review: Following the Path From Online Intake to Refills

01Start with the organizations behind the service

Gimme Care is the consumer-facing platform, not the entity claiming to perform every step of treatment. Its terms identify Start Gimme, LLC and affiliates as the website operators and explicitly state that Gimme does not provide medical services. Instead, medical services come through a contracted network of healthcare professionals described as licensed in the patient's state. The terms name Bask Telehealth LLC as the telehealth channel and give its mailing address as 555 Madison Ave., Suite 1202, New York, NY 10022.

That division matters when a question changes from an account issue to a clinical concern. Gimme also says it is not a pharmacy: it connects patients with professionals who determine treatment eligibility. These are the company's descriptions, not independent licensing checks. Before paying, ask which organization handles clinical messages, which clinician will review the intake and which pharmacy will dispense the prescription. Our guide to the clinician-platform distinction explains why a recognizable website name does not identify every participant in care.

02The questionnaire opens a review, not a guaranteed prescription

Gimme's advertised entry point is an online questionnaire about health and goals. A licensed healthcare professional reviews that information and prescribes only if treatment is medically appropriate. The consulted pages do not establish specific BMI thresholds, required comorbidities, mandatory laboratory tests or a complete list of exclusions for these plans. They also do not provide a general numerical deadline for clinical review. A completed form should therefore not be treated as approval, a guaranteed prescription or a promise that medication will leave the pharmacy immediately.

The company advertises service in all 50 states and the District of Columbia, while acknowledging different consultation pathways. In most states, it says treatment can begin without a video visit, and patients can request one through the portal. Kansas, Louisiana, Mississippi, New Mexico and West Virginia require a brief video or audio visit before starting. The terms describe an intended audience of adults 18 and older and say some services may require age over 21. An additional parental-consent clause does not, by itself, establish clinical eligibility for minors.

03The pharmacy handoff needs more detail than an ingredient name

The documented weight-management products are compounded semaglutide and compounded tirzepatide, each described as a subcutaneous injection. Those listings do not confirm oral or sublingual alternatives. Gimme says its compounded GLP-1 medicines come exclusively from US pharmacies, but the consulted documentation does not identify the dispensing pharmacies by name. It also leaves concentrations, additional ingredients, actual presentation, quantity per shipment and storage requirements unresolved. Those are product-identification gaps to close with the prescriber and dispensing pharmacy, rather than details to infer from the plan name.

Gimme discloses that these compounded formulations are not FDA approved and have not undergone clinical trials evaluating their safety, efficacy or therapeutic equivalence to approved medicines. FDA recommends compounded drugs when an individual's medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence, but neither does an ingredient name establish equivalence. The useful next step is a documented pharmacy handoff: identify the pharmacy, the prescribed product and the contact responsible for medication questions.

04Read the price alongside the service responsibilities

Gimme publishes separate prices for its two compounded injectable programs, rather than one universal GLP-1 rate. Its general homepage pricing answer gives $130 per month billed every three months or $160 month to month, without naming the medicine in that answer. Those figures match the semaglutide listing and should not be applied to tirzepatide. The product pages display six-month monthly rates, but do not establish complete upfront collection terms, unused-balance treatment or renewal pricing. A longer package label also does not establish the quantity supplied in any shipment.

The homepage says its quoted plan includes medication, physician care, support, shipping and supplies, with no membership costs or hidden fees. Tirzepatide's page specifically includes consultation and care, advertises unlimited support and says the price is the same at every dose. These are provider claims about the bundle; the documentation does not confirm inclusion of laboratory tests or outside services. The terms also make this cash-pay care: Gimme and the professionals do not accept commercial insurance, are not in-network and are not enrolled in Medicare or Medicaid.

05Dispatch, delivery and a usable shipment are separate milestones

Gimme advertises discreet, free home delivery without a pharmacy visit and uses a commercial delivery guarantee without a numerical arrival deadline. Its refill description is more specific: shipments every 28 days after a short check-in, with tracking through the portal. That is a dispatch interval, not a promise of arrival every 28 days. Four weeks also differs from a calendar month. The consulted pages do not establish typical first-shipment timing, transit duration or how the refill clock interacts with the one-, three- and six-month billing cycles.

Delivery problems have their own process. Gimme asks patients to report damaged or defective medicine within 48 hours of delivery, with photographs of the medication and original packaging. If confirmed, replacement is free; a refund is offered only when replacement is impossible. Confirmed incorrect orders also qualify for shipment of the correct medicine without an additional charge. Separately, FDA explicitly advises not using injectable GLP-1 medicine that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. Our cold-chain guide explains that advice; Gimme's own detailed temperature-handling procedure remains undocumented here.

06Follow-up is documented, but response times are not

Gimme advertises unlimited provider messaging for follow-ups, adjustments and questions. Its portal also offers support chat, weight tracking, refill management and shipment updates. That is a more developed description than simply promising access to an account dashboard. Still, the refill check-in is described only as short: the consulted pages do not explain its clinical contents, who reviews it or what happens if a review delays the next shipment. No general numerical response target for clinical messages is established, so message access should not be confused with immediate clinical availability.

The homepage's broad availability language also needs to be read alongside the refund policy's stated support hours of 8 a.m. to 8 p.m. Eastern Time. That schedule does not establish round-the-clock clinician coverage. For continuity, ask how medication questions are routed and what happens when the usual professional is unavailable. NIDDK describes follow-up as addressing tolerability and response, not merely renewing payments. Gimme's terms add a privacy consideration: ordinary text messages and emails are not encrypted and may be intercepted. The consulted text does not establish a usable email address.

07Stopping the subscription is not the same as reversing an order

Gimme's policy makes subscriptions the default unless checkout states otherwise; any one-time purchase should be identified there. Subscription details and cancellation options are available in the patient portal. The main order rule allows cancellation before pharmacy dispensing or shipment, but not after either event. Other passages discuss cancellation only before shipping, creating an ambiguity for an order already dispensed but not yet dispatched. The earlier boundary is the important one to clarify before relying on an account cancellation to stop a particular prescription order.

For an order successfully canceled before shipping, the policy promises a full refund within five to ten business days. Otherwise, dispensed or shipped prescription medicines cannot be returned and sales are generally final. Limited refund reviews require an order number, purchase date, explanation and potentially supporting documentation. Gimme gives five to seven business days for review and, if approved, another five to ten business days to issue the refund to the original payment method. Issuance is not guaranteed bank receipt. These distinctions make changing-program questions relevant before the next refill, not only after a charge appears.

08The four-month promise is a separate, conditional process

The Gimme Progress Promise is not an unconditional extension of the general refund policy. It applies to first-time members who remain enrolled for four consecutive months after their first prescription, follow clinician instructions and keep their account in good standing. Within 14 days of that first prescription, they must submit a continuous, unedited baseline video showing themselves appropriately clothed on a scale placed on a hard surface, with a visible reading and verbal confirmation of their name and date. That early documentation requirement matters long before someone knows whether they will submit a claim.

A claim for lack of measurable progress must be submitted within 14 days after the four-month mark. The consulted passages do not define a uniform numerical progress threshold. If approved, Gimme may refund the first four months' payments; it says most approved claims receive that full amount, while retaining discretion based on participation and incurred costs. Approved refunds are issued within 30 days of approval, to the original payment method whenever possible. A prior chargeback or payment dispute excludes an additional Promise refund. Gimme expressly calls this a satisfaction policy, not insurance, a medical warranty or a guaranteed weight-loss outcome.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Gimme Care — policies/terms of service ↗
4. Gimme Care — official website ↗
5. Gimme Care — policies/refund policy ↗
6. Gimme Care — treatments/compounded tirzepatide ↗
7. Gimme Care — treatments/compounded semaglutide ↗

Continue reading

• The GLP-1 Care Journey: Who Handles Intake, Prescribing, Delivery and Follow-Up?
• Who Provides Your Care When You Use a Telehealth Platform?
• From Prescription to Dispensing: Questions for the GLP-1 Pharmacy Handoff
• When Injectable Medicine Arrives Warm: Reading the FDA Advice
• Before You Stop Payments or Change a GLP-1 Program, Ask Who Still Owns Your Care